

Results of Annual General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") today held an Annual General Meeting of Members at the offices of BDO Australia, Level 9, Mia Yellagonga Tower 2, 5 Spring St, Perth WA 6000.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

Authority

This announcement has been authorised for release by the Company Secretary of Neurotech International Limited.

Investors:

Dr Thomas Duthy

Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company will commence a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY23. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Disclosure of Proxy Votes

Neurotech International Limited

Annual General Meeting

Wednesday, 30 November 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of the Remuneration Report	P	126,490,291	125,652,943 99.34%	759,879 0.60%	22,723,572	77,469 0.06%	143,598,756 99.47%	759,879 0.53%	30,516,589
2 Election of Dr Thomas Duthy	P	154,316,299	153,937,951 99.75%	320,879 0.21%	30,000	57,469 0.04%	181,656,781 99.82%	320,879 0.18%	30,000
3 Election of Mr Gerald Quigley	P	154,346,299	154,190,391 99.90%	98,439 0.06%	0	57,469 0.04%	181,909,221 99.95%	98,439 0.05%	0
4 Re-election of Mr Winton Willesee	P	154,316,299	153,547,951 99.50%	710,879 0.46%	30,000	57,469 0.04%	181,266,781 99.61%	710,879 0.39%	30,000
5 Approval of Additional 10% Placement Capacity	P	107,523,627	106,248,690 98.81%	1,067,468 0.99%	30,000	207,469 0.19%	118,117,520 99.10%	1,067,468 0.90%	30,000
6 Issue of Options to Dr Thomas Duthy	P	149,183,863	148,301,515 99.41%	804,879 0.54%	30,000	77,469 0.05%	173,272,001 99.54%	804,879 0.46%	30,000
7 Issue of Options to Professor Allan Cripps AO	P	149,213,863	148,553,955 99.56%	582,439 0.39%	0	77,469 0.05%	173,524,441 99.67%	582,439 0.33%	0



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Issue of Options to Gerald Quigley	P	149,213,863	148,553,955 99.56%	582,439 0.39%	0	77,469 0.05%	173,524,441 99.67%	582,439 0.33%	768,344
9 Issue of Options to Winx Capital	P	154,306,549	125,566,193 81.37%	836,879 0.54%	39,750	27,903,477 18.08%	181,131,031 99.54%	836,879 0.46%	39,750
10 Issue of Milestone Shares to Dolce Cann Global Pty Ltd	P	154,306,549	125,870,072 81.57%	553,000 0.36%	39,750	27,883,477 18.07%	181,414,910 99.70%	553,000 0.30%	39,750

